Vascular Biogenics Company Profile (NASDAQ:VBLT)

About Vascular Biogenics

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBLT
  • CUSIP:
Key Metrics:
  • Previous Close: $5.16
  • 50 Day Moving Average: $4.33
  • 200 Day Moving Average: $3.91
  • 52-Week Range: $2.76 - $8.54
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.76
  • P/E Growth: 0.00
  • Market Cap: $132.17M
  • Outstanding Shares: 23,602,000
  • Beta: -3.5
Profitability:
  • Return on Equity: -48.79%
  • Return on Assets: -43.28%
Debt:
  • Current Ratio: 12.75%
  • Quick Ratio: 12.75%
Additional Links:
Companies Related to Vascular Biogenics:

Analyst Ratings

Consensus Ratings for Vascular Biogenics (NASDAQ:VBLT) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $15.50 (193.56% upside)
Analysts' Ratings History for Vascular Biogenics (NASDAQ:VBLT)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016Roth CapitalReiterated RatingBuy$17.00View Rating Details
6/28/2016HC WainwrightInitiated CoverageBuy$11.00View Rating Details
6/7/2016Chardan CapitalReiterated RatingBuyView Rating Details
6/7/2016Piper Jaffray Cos.Reiterated RatingBuy$14.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00View Rating Details
11/13/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
1/22/2015Deutsche Bank AGBoost Price Target$12.00 -> $19.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Vascular Biogenics (NASDAQ:VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016        
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Biogenics (NASDAQ:VBLT)
Current Year EPS Consensus Estimate: $-0.64 EPS
Next Year EPS Consensus Estimate: $-0.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vascular Biogenics (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ:VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Vascular Biogenics (NASDAQ:VBLT)
DateHeadline
zacks.com logoVascular Biogenics (VBLT) Jumps: Stock Moves 8.5% Higher (NASDAQ:VBLT)
www.zacks.com - September 28 at 7:55 AM
investornewswire.com logoShares Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Expected To Hit $20 - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - September 25 at 7:43 AM
News IconHow Many Vascular Biogenics Ltd (NASDAQ:VBLT)'s Analysts Are Bearish? - Post News (NASDAQ:VBLT)
www.kentuckypostnews.com - September 24 at 7:48 AM
News IconVascular Biogenics Ltd (VBLT) Receives “Buy” Rating from Roth ... - DailyQuint (NASDAQ:VBLT)
dailyquint.com - September 22 at 7:25 AM
News IconLooking Ahead for Vascular Biogenics Ltd. (NASDAQ:VBLT); Are These Shares Ready to Go Higher? - Frisco Fastball (NASDAQ:VBLT)
friscofastball.com - September 21 at 11:47 AM
News IconVascular Biogenics Ltd (VBLT) Rating Reiterated by Chardan Capital - DailyQuint (NASDAQ:VBLT)
dailyquint.com - September 21 at 11:47 AM
marketexclusive.com logoVBL Therapeutics CEO tells us about their revolutionary approach to cure cancer – Vascular Biogenics Ltd (NASDAQ:VBLT) (NASDAQ:VBLT)
marketexclusive.com - September 16 at 7:37 PM
marketexclusive.com logoVBL Therapeutics CEO tells us about their revolutionary approach to cure cancer - Vascular Biogenics Ltd (NASDAQ ... - Market Exclusive (NASDAQ:VBLT)
marketexclusive.com - September 16 at 11:35 AM
finance.yahoo.com logoEarnings Estimates Moving Higher for Vascular Biogenics (VBLT): Time to Buy? (NASDAQ:VBLT)
finance.yahoo.com - September 14 at 12:19 PM
News IconShares in Focus: Vascular Biogenics Ltd. (NASDAQ:VBLT) Earnings & Targets Update - Frisco Fastball (NASDAQ:VBLT)
friscofastball.com - September 13 at 7:46 AM
News IconPlacing Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares Under the Microscope - Post News (NASDAQ:VBLT)
www.kentuckypostnews.com - September 8 at 11:52 AM
einnews.com logoVBL Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on ... (NASDAQ:VBLT)
semiconductors.einnews.com - September 6 at 8:02 PM
finance.yahoo.com logoVBL Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12th, 2016 (NASDAQ:VBLT)
finance.yahoo.com - September 6 at 8:02 PM
investornewswire.com logoCan Shares Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Get To $20? - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - September 3 at 6:56 PM
News IconHC Stocks Growth - Vascular Biogenics Ltd (NASDAQ:VBLT), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NASDAQ:VBLT)
sharemarketupdates.com - September 1 at 11:13 AM
News IconShares Gapping Down Before the Open: Vascular Biogenics Ltd. (NASDAQ:VBLT) - Post News (NASDAQ:VBLT)
www.kentuckypostnews.com - August 26 at 7:41 PM
live-pr.com logoNew Report Available: Vascular Biogenics Ltd. (VBLT) - Financial and Strategic SWOT Analysis Review (NASDAQ:VBLT)
www.live-pr.com - August 24 at 7:49 PM
News IconWHERE TO BUY VIAGRA - Buy Generic Viagra India (NASDAQ:VBLT)
roslyn-news.com - August 22 at 8:00 PM
investornewswire.com logoWill Vascular Biogenics Ltd. (NASDAQ:VBLT) Hit $20 Price Target? - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - August 20 at 7:33 PM
News IconCrowd Sentiment & Analyst Review on Vascular Biogenics Ltd. (NASDAQ:VBLT) - Post News (NASDAQ:VBLT)
www.kentuckypostnews.com - August 20 at 11:43 AM
4-traders.com logoVBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:VBLT)
www.4-traders.com - August 15 at 10:09 AM
sg.finance.yahoo.com logoVascular Biogenics reports 2Q loss (NASDAQ:VBLT)
sg.finance.yahoo.com - August 15 at 10:09 AM
publicnow.com logoBioLineRx Names Philip A. Serlin as Chief Executive Officer (NASDAQ:VBLT)
www.publicnow.com - August 11 at 11:33 AM
publicnow.com logoVBL Therapeutics to Report Second Quarter 2016 Financial Results on August 15 (NASDAQ:VBLT)
www.publicnow.com - July 26 at 8:38 AM
News IconVascular Biogenics Ltd. (NASDAQ:VBLT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:VBLT)
www.engelwooddaily.com - July 20 at 10:58 AM
News IconTrading Performance and Target Watch for Vascular Biogenics Ltd. (NASDAQ:VBLT) - Press Telegraph (NASDAQ:VBLT)
presstelegraph.com - July 18 at 7:42 AM
investornewswire.com logoStrong Sell Calls For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - July 17 at 7:48 AM
ftsenews.co.uk logoVascular Biogenics Ltd. (VBLT) Updated Price Targets - FTSE News (NASDAQ:VBLT)
www.ftsenews.co.uk - July 14 at 11:45 AM
News IconAnalyst Target and Average Rating Watch: Vascular Biogenics Ltd. (NASDAQ:VBLT) - Press Telegraph (NASDAQ:VBLT)
presstelegraph.com - July 13 at 8:25 PM
investornewswire.com logoIs $22 Within Reach For Vascular Biogenics Ltd. (NASDAQ:VBLT)? - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - July 9 at 7:18 PM
ftsenews.co.uk logoNew Broker Ratings For Vascular Biogenics Ltd. (VBLT) - FTSE News (NASDAQ:VBLT)
www.ftsenews.co.uk - July 8 at 10:53 AM
breakingfinancenews.com logoVascular Biogenics Ltd (NASDAQ:VBLT) target price raised to $11 as covered today by H.C. Wainwright - Breaking Finance News (NASDAQ:VBLT)
breakingfinancenews.com - July 4 at 7:44 AM
breakingfinancenews.com logoVascular Biogenics Ltd (NASDAQ:VBLT) target price raised to $11 as covered today by H.C. Wainwright (NASDAQ:VBLT)
breakingfinancenews.com - July 3 at 7:13 PM
247wallst.com logo7 Analyst Stock Picks Under $10 With Massive Upside Calls (NASDAQ:VBLT)
247wallst.com - July 2 at 10:01 AM
News IconHC Stocks Growth: Vascular Biogenics Ltd (NASDAQ:VBLT), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NASDAQ:VBLT)
sharemarketupdates.com - July 1 at 10:44 AM
stocksdaily.net logoCan Vascular Biogenics Ltd. (NASDAQ:VBLT) Meet Analysts Expectations? - Stocks Daily (NASDAQ:VBLT)
www.stocksdaily.net - June 30 at 8:17 PM
News IconAnalyst Rating Update on Vascular Biogenics Ltd. (VBLT) - TheFounders Daily (NASDAQ:VBLT)
www.thefoundersdaily.com - June 30 at 8:17 PM
benzinga.com logoH.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics (NASDAQ:VBLT)
www.benzinga.com - June 29 at 7:59 PM
streetinsider.com logoH.C. Wainwright Starts Vascular Biogenics Ltd (VBLT) at Buy - StreetInsider.com (NASDAQ:VBLT)
www.streetinsider.com - June 28 at 8:00 PM
finance.yahoo.com logoCoverage initiated on VBL Therapeutics by H.C. Wainwright (NASDAQ:VBLT)
finance.yahoo.com - June 28 at 7:07 AM
kcregister.com logoHot Stocks: Neuralstem, Inc. (NASDAQ:CUR), Vascular Biogenics Ltd. (NASDAQ:VBLT), Accelerate Diagnostics, Inc ... - KC Register (NASDAQ:VBLT)
www.kcregister.com - June 27 at 7:53 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Vascular Biogenics Ltd. (VBLT) - Fiscal Standard (NASDAQ:VBLT)
www.fiscalstandard.com - June 27 at 7:39 AM
investornewswire.com logoStrong Sell Calls Recommendations For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - June 26 at 7:38 AM
News IconVascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Rating Consensus - TheFounders Daily (NASDAQ:VBLT)
www.thefoundersdaily.com - June 22 at 7:46 AM
fiscalstandard.com logoVascular Biogenics Ltd. (VBLT) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:VBLT)
www.fiscalstandard.com - June 21 at 7:29 AM
publicnow.com logoVBL Therapeutics Announces Appointment of Dr. Rachel W. Humphrey to Head of the Scientific Advisory Board (NASDAQ:VBLT)
www.publicnow.com - June 21 at 7:19 AM
fiscalstandard.com logoVascular Biogenics Ltd. (VBLT) Current Analyst Ratings - Fiscal Standard (NASDAQ:VBLT)
www.fiscalstandard.com - June 17 at 10:45 AM
publicnow.com logoVascular Biogenics Ltd. Closes $24 Million Registered Direct Offering (NASDAQ:VBLT)
www.publicnow.com - June 16 at 12:49 PM
News IconStock's Earnings Analysis: STORE Capital Corporation (NYSE:STOR), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle (NASDAQ:VBLT)
www.beaconchronicle.com - June 13 at 11:03 AM
streetupdates.com logoInvestors Focused Stocks: Array BioPharma Inc. (NASDAQ:ARRY) , Vascular Biogenics Ltd. (NASDAQ:VBLT) - Street Updates (NASDAQ:VBLT)
www.streetupdates.com - June 10 at 11:12 AM

Social

Vascular Biogenics (NASDAQ:VBLT) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff